Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019024776) PHARMACEUTICAL COMPOSITION AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/024776 International Application No.: PCT/CN2018/097380
Publication Date: 07.02.2019 International Filing Date: 27.07.2018
IPC:
A61K 45/06 (2006.01) ,A61K 31/41 (2006.01) ,A61P 1/16 (2006.01) ,A61P 3/06 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1
Drugs for disorders of the alimentary tract or the digestive system
16
for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3
Drugs for disorders of the metabolism
06
Antihyperlipidemics
Applicants:
武汉朗来科技发展有限公司 WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. [CN/CN]; 中国湖北省武汉市 东湖新技术开发区高新大道666号武汉国家生物产业基地研发区C2-2 Biolake C2-2, No.666 High-tech Road, East Lake High-tech Development Zone Wuhan, Hubei 430075, CN
武汉启瑞药业有限公司 WUHAN QR PHARMACEUTICALS CO., LTD. [CN/CN]; 中国湖北省武汉市 东湖新技术开发区庙山小区 Miaoshan Pilot, Wuhan East Lake High-tech Development Zone Wuhan, Hubei 430223, CN
Inventors:
郭晓丹 GUO, Xiaodan; CN
陈永凯 CHEN, Yongkai; CN
冯伟 FENG, Wei; CN
钱丽娜 QIAN, Lina; CN
王朝东 WANG, Chaodong; CN
Agent:
武汉智元知识产权代理事务所(普通合伙) WUHAN ORIGINTELLIGENCE IP LAW FIRM; 中国湖北省武汉市 洪山区光谷大道62号光谷总部国际1栋912室张炳楠 ZHANG, Bingnan Room 912, Building 1, Optics Valley Headquarters International, No. 62 Optics Valley Avenue, Hongshan District Wuhan, Hubei 430074, CN
Priority Data:
201710641321.331.07.2017CN
Title (EN) PHARMACEUTICAL COMPOSITION AND USE THEREOF
(FR) COMPOSITION PHARMACEUTIQUE ET SON UTILISATION
(ZH) 药物组合物及其用途
Abstract:
(EN) Disclosed is a pharmaceutical composition, comprising a first component and a second component, wherein the first component is selected from at least one of an ASK1 inhibitor and a precursor, an active metabolite, a stereisomer, a pharmaceutically acceptable salt, an ester and a solvate thereof; and the second component is selected from at least one of a PPAR modifier, and a precursor, an active metabolite, a stereisomer, a pharmaceutically acceptable salt, an ester and a solvate thereof. Also disclosed is a pharmaceutical preparation comprising the pharmaceutical composition. Also disclosed is a use of the pharmaceutical composition in the preparation of a medicament for treating and/or preventing nonalcoholic fatty liver or nonalcoholic steatohepatitis, reducing levels of total cholesterol, lowering liver coefficient, increasing high-density lipoprotein cholesterol, and/or improving NAS score and/or fibrosis score.
(FR) L'invention concerne une composition pharmaceutique comprenant un premier constituant et un second constituant, le premier constituant étant sélectionné parmi au moins l'un des composés suivants : un inhibiteur de ASK1 et un précurseur, métabolite actif, stéréisomère, sel pharmaceutiquement acceptable, ester et solvate de ce dernier; et le second constituant étant sélectionné parmi au moins l'un des composés suivants : un modificateur de PPAR, et un précurseur, métabolite actif, stéréisomère, sel pharmaceutiquement acceptable, ester et solvate correspondant. L'invention concerne également une préparation pharmaceutique comprenant la composition pharmaceutique. L'invention concerne également une utilisation de la composition pharmaceutique dans la préparation d'un médicament pour traiter et/ou prévenir la stéatose hépatique non alcoolique ou la stéatohépatite non alcoolique, faire baisser le taux de cholestérol total, abaisser le coefficient hépatique, augmenter le taux des lipoprotéines de haute densité liées au cholestérol, et/ou améliorer le score NAS et/ou le score de fibrose.
(ZH) 一种药物组合物,包括第一组分和第二组分,第一组分为选自ASK1抑制剂及其前体、活性代谢产物、立体异构体、药学上可接受的盐、酯类和溶剂合物中的至少一种;第二组分为选自PPAR调节剂及其前体、活性代谢产物、立体异构体、药学上可接受的盐、酯类和溶剂合物中的至少一种。包含该药物组合物的药物制剂。该药物组合物在制备治疗和/或预防非酒精性脂肪肝或非酒精性脂肪性肝炎、降低总胆固醇等水平、降低肝系数、升高高密度脂蛋白胆固醇和/或改善NAS评分和/或纤维化评分等的药物中的用途。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)